The effects of calcitonin on idiopathic nephrolithiasis. Evidence of bone involvement in fasting hypercalciuria.
This study was performed to evaluate the antihypercalciuric effect of calcitonin (CT), a potent inhibitor of bone osteoclastic activity, on idiopathic hypercalciuria (IH). Forty-two stone formers were studied: 18 suffered from fasting hypercalciuria (FH), 12 from nonfasting hypercalciuria (NFH) and 12 were normocalciuric stone formers (NSF). All patients received CT, 25 U/day sc for a period of 15 days. CT caused a statistically significant drop in urine calcium, phosphorus and hydroxyproline (OH-proline) excretion in FH patients and a concomitant increase in serum PTH levels. In this group the percentage variation (D%) of urine calcium decrease was linearly correlated with D% decrease in urine OH-proline. These results support the hypothesis that pathological bone reabsorption might be involved in the genesis of FH.
Filipponi
P
P
Istituto di Clinica Medica I, University of Perugia, Italy.
Mannarelli
C
C
Gubbiotti
G
G
Blass
A
A
Moretti
I
I
Tini
S
S
Giuseppetti
N
N
Ballanti
S
S
Morucci
P
P
D002116:Calcitonin / Q000627:therapeutic use*; D002118:Calcium / Q000652:urine*; D005215:Fasting; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007669:Kidney Calculi / Q000097:blood / Q000188:drug therapy / Q000652:urine*; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000652:urine
D010281:Parathyroid Hormone; D010758:Phosphorus; D002116:Calcitonin; D006909:Hydroxyproline; D002118:Calcium